CONFERENCE COVERAGE SERIES
European Medicines Agency’s Expert Meeting in Familial Neurodegenerative Disorders
European Medicines Agency, London, England
08 November 2010
In November 2010, officials from European and U.S. drug regulatory agencies met in London with Alzheimer's and Huntington's scientists in academia and pharma to grapple collectively with the prospect of something that has never been done before: Test experimental drugs in asymptomatic carriers of autosomal-dominant AD mutations. Those are the folks who will get AD with certainty and live every day either with that knowledge or at least the fear.
The biology of the disease is already unfolding in them, but they are outwardly healthy. "We learned convincingly that autosomal-dominant patients have been excluded, and now realize they could be an extremely valuable population for trials," concluded one senior official at the European Medicines Agency. Read Gabrielle Strobel's full account.
London: Europe-U.S. Regulators Mull Prevention Trial in Familial AD
The charge of this meeting was to begin a dialogue toward the shared goal of offering therapeutic treatment and prevention trials to families with autosomal-dominant AD...
London: What, No Argument? Speakers Agree on Trials for Familial AD
Part 2 of Alzforum’s coverage continues with what scientists from inside and outside DIAN said about the prospect of such pre-symptomatic trials...
London: What Regulators Say About Trials in Familial AD
Eight EMA officials and nine FDA officials took part in a discussion about preclinical trials in autosomal-dominant AD...
London: Families Talk About Treatment Trials
Autosomal-dominant Alzheimer's and Huntington's disease family representatives spoke or showed videos about treatment trials...